Apellis Pharmaceuticals (APLS) Financials

$41.03

$0.00 (0.00%)

As on 15-May-2026 16:00EDT

Market cap

$5,253 Mln

Revenue (TTM)

$1,105 Mln

P/E Ratio

38.3

P/B Ratio

12.7

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	1,105.28	1,003.78	781.37	396.59	75.42	66.56
Cost of Revenue	109.16	102.24	117.72	58.51	5.64	5.20
Gross Profit	996.12	901.55	663.64	338.08	69.79	61.36
Operating Expenses	831.19	846.12	828.62	855.20	664.40	597.64
Operating Profit (EBIT)	165.22	55.43	-164.98	-517.12	-594.61	-536.28
Other Income	--	--	--	--	--	--
Profit before Tax	135.15	24.11	-196.72	-526.50	-651.50	-746.00
Provision for Tax	1.88	1.72	1.16	2.13	0.67	0.35
Profit after Tax (Net Income)	133.27	22.39	-197.88	-528.63	-652.17	-746.35
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-652.17	-746.35

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	414.92	370.15	228.54	194.52	169.87	198.66
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	384.16	381.51	471.00	346.62	422.74	551.26
Current Liabilities	283.45	323.60	185.51	247.59	167.61	131.85
Total Liabilities	1,365.98	1,075.26	885.05	788.73	760.22	881.77

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	54.51	60.42	96.10	22.40	40.69	57.72
Current Assets	1,028.02	1,014.84	788.95	766.33	719.52	824.05
Total Assets	1,365.98	1,075.26	885.05	788.73	760.22	881.77
Total Debt*	475.76	486.31	469.78	110.93	112.71	210.22
Net Current Assets	744.57	691.24	603.45	518.74	551.91	692.20

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	45.33	-87.87	-594.74	-513.75	-563.13
Cash Flow from Investing Activities	--	-0.31	-0.40	-0.67	59.89	247.62
Cash from Financing Activities	--	8.88	149.24	394.50	365.66	392.24
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	1.06	0.18	-1.60	-4.36	-5.90	-8.71
Cash EPS ($)	--	0.19	-1.58	-4.35	-5.88	-8.70
Adjusted Book Value ($)	--	2.94	1.84	1.60	1.54	2.32
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	0.36	-0.71	-4.91	-4.64	-6.57
Free Cash Flow per Share ($)	--	0.36	-0.71	-4.91	-4.66	-6.59

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	2.88	-39.43	-179.80	-188.63	-150.60
ROE (%)	32.66	7.48	-93.55	-290.14	-353.93	-370.20
ROA (%)	11.33	2.28	-23.64	-68.26	-79.44	-81.02
EBIT Margin (%)	16.17	6.82	-20.01	-125.30	-820.55	-1,100.85
Net Margin (%)	12.06	2.23	-25.32	-133.29	-864.70	-1,121.27
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	42.46	0.28	0.97	4.26	0.13	-0.73
EBIT Growth (%)	200.49	143.78	68.54	19.71	15.54	-134.04
Net Profit Growth (%)	159.58	111.31	62.57	18.94	12.62	-116.41
EPS Growth (%)	158.88	1.11	0.63	0.26	0.32	-1.00
Book Value Growth (%)	151.52	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	38.35	141.40	-19.98	-13.73	-8.77	-5.43
Price / Book Value	12.66	8.55	17.30	37.31	33.68	20.39
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	29.55	45.49	-25.93	-14.17	-8.54	-4.87
Close Price ($)	40.23	25.12	31.91	59.86	51.71	47.28
High Price ($)	40.45	35.57	73.80	94.75	70.00	73.00
Low Price ($)	16.10	16.10	24.34	19.83	33.32	27.50
Market Cap ($ Cr)	5,252.71	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	0.87	1.31	2.06	0.57	0.66	1.06
Short term debt to equity ratio	0.24	0.27	0.03	0.03	0.03	0.02
Current Ratio	3.63	3.14	4.25	3.10	4.29	6.25
Quick Ratio	3.16	2.70	3.81	2.50	3.78	6.07
Interest Coverage	4.10	1.54	-3.87	-16.80	-18.97	-55.34

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	40.27	36.48	34.78	52.05	10.25	120.34
Asset Turnover	0.94	1.02	0.93	0.51	0.09	0.07
Receivable days	--	116.07	111.76	98.62	212.67	288.36
Inventory Days	--	401.99	355.01	724.37	3,555.19	842.99
Payable days	--	170.36	118.04	233.65	1,757.91	891.56
Cash Conversion Cycle	--	347.70	348.73	589.34	2,009.95	239.79

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.